Gilead's Viread approved in US for chronic hepatitis B
This article was originally published in Scrip
Executive Summary
Gilead Sciences' oral anti-HIV drug Viread (tenofovir disoproxil fumarate) has been approved for the treatment of chronic hepatitis B in adults by the USFDA.
You may also be interested in...
Targacept/AstraZeneca Alzheimer's hope fails in Phase II
Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.
Amgen reveals more details of denosumab's fracture benefit
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GSK and Xenoport file restless legs drug Solzira in US
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.
Need a specific report? 1000+ reports available
Buy Reports